Weekly Research Analysts’ Ratings Updates for LB Pharmaceuticals (LBRX)

A number of firms have modified their ratings and price targets on shares of LB Pharmaceuticals (NASDAQ: LBRX) recently:

• 8/3/2026 – LB Pharmaceuticals had its “overweight” rating reaffirmed by Piper Sandler. They now have a $78.00 price target on the stock.
• 8/3/2026 – LB Pharmaceuticals had its “buy” rating reaffirmed by HC Wainwright. They now have a $45.00 price target on the stock.
• 7/24/2026 – LB Pharmaceuticals was upgraded by Weiss Ratings from “sell (d-)” to “sell (d+)”.
• 7/24/2026 – LB Pharmaceuticals had its “buy” rating reaffirmed by HC Wainwright.
• 7/20/2026 – LB Pharmaceuticals is now covered by BMO Capital Markets. They set an “outperform” rating and a $46.00 price target on the stock.
• 7/20/2026 – LB Pharmaceuticals was upgraded by BMO Capital Markets to “strong-buy”.
• 7/7/2026 – LB Pharmaceuticals is now covered by Wolfe Research. They set an “outperform” rating and a $45.00 price target on the stock.
• 6/22/2026 – LB Pharmaceuticals had its “buy” rating reaffirmed by HC Wainwright.
• 6/21/2026 – LB Pharmaceuticals was upgraded by Wall Street Zen from “sell” to “hold”.
• 6/13/2026 – LB Pharmaceuticals was downgraded by Wall Street Zen from “hold” to “sell”.
• 6/11/2026 – LB Pharmaceuticals was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.

We are a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. We are building a pipeline that leverages the broad therapeutic potential of our lead product candidate, LB-102, which we believe has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in over 50 countries, not including the United States, because the development and regulatory requirements of the U.S.